International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationAn Interindividual Comparison of O-(2- [18F]Fluoroethyl)-L-Tyrosine (FET)– and L-[Methyl-11C]Methionine (MET)–PET in Patients With Brain Gliomas and Metastases
Introduction
In brain tumors treatment planning and evaluation of local response to therapy are usually based on magnetic resonance imaging (MRI) and computed tomography (CT). These investigations show the anatomy of the brain with high accuracy. However, the correlation between real tumor extension and the radiologic imaging of the malignant tissue on CT or MRI is quite different for gliomas and brain metastases. In brain gliomas stereotactic biopsy specimens showed that malignant tissue could be located far beyond the margins of the tumor visualized on MRI or CT 1, 2, 3, 4. In contrast, in brain metastases the correlation between real tumor extension and the imaging of the lesions on MRI or CT is very high 5, 6, 7. In both gliomas and metastases treatment-related changes (TRCs) (after radiochemotherapy, also called “pseudoprogression”) such as blood–brain barrier (BBB) disturbance or edema can generally not be differentiated from viable tumor tissue 8, 9.
Several studies suggest that because of its high sensitivity and specificity for tumor tissue, L-[methyl-11C]methionine (MET)–positron emission tomography (PET) is a useful tool for the visualization of brain tumors 10, 11, 12, 13, 14, 15. MET is transported across the BBB by the L-type amino acid transport system and intensely accumulated by tumor cells. Disruption of the BBB is therefore not necessary for MET accumulation in the tumor tissue. In a intracellular manner, MET can enter multiple metabolic pathways. However, studies have indicated that at the time of PET imaging, tumor uptake of MET mainly reflects AA transport (16). When we compare CT, MRI, and MET-PET with stereotactic biopsy in brain gliomas, MET-PET has shown a significantly higher accuracy in defining the extent of tumor than CT and MRI 10, 11, 12, 13, 14, 15. Therefore MET-PET can improve tumor delineation for surgery 17, 18 or radiation therapy planning 19, 20, 21 and could have an impact on the evaluation of treatment outcome. Nevertheless, the application of MET-PET has been limited to a small number of research centers, because the short physical half-life of 11C (20 minutes) necessitates an onsite cyclotron for MET-PET examinations.
O-(2- [18F]fluoroethyl)-L-tyrosine (FET) is an analog of tyrosine that is not metabolized and not incorporated into proteins. The uptake by tumor cells is mediated by the L-type AA transport system 22, 23. The sensitivity and specificity for tumor tissue, evaluated by use of stereotactic biopsy specimens, are higher for FET-PET than for MRI and CT 24, 25, 26. In contrast to MET the physical half-life for 18F (110 minutes) allows FET-PET studies to be performed in centers without an onsite cyclotron. Similar transport characteristics for FET and MET were shown in studies using F98 rat glioma cells (27). In a previous clinical study we observed a close correlation between the intensity of MET and FET uptake in tumoral and non-tumoral cerebral lesions (28). However, this trial included only 16 patients and did not assess differences in tumor extension between the two imaging modalities.
The aim of this study was to perform an intraindividual comparison of FET-PET and MET-PET in patients with brain gliomas or metastases. Tracer uptake in normal and tumor tissue, sensitivity and specificity for differentiation of tumor tissue vs. TRCs, and macroscopic tumor extension were compared for FET-PET and MET-PET.
Section snippets
Patients
Forty-two consecutive patients were included in the study within 24 months. All patients had previously been treated for gliomas or brain metastases (Table 1) and now presented with MRI findings suggesting the presence of residual or recurrent tumor tissue. Of the patients, 29 had a high-grade (n = 25) or low-grade (n = 4) glioma and 13 had had brain metastases. The patient population includes 16 patients who were reported on previously (28).
In all patients the two FET- and MET-PET studies were
Uptake of MET and FET in normal gray matter and lesions
Time–activity curves showed a similar time course of MET and FET uptake by normal gray matter and lesions. L-[methyl-11C]methionine uptake reached a plateau within 10 minutes. O-(2- [18F]fluoroethyl)-L-tyrosine uptake was somewhat slower and plateaued within 20 minutes. Thus, for further analysis, MET-PET images were summed between 10 and 30 minutes part injection, and FET-PET images were summed between 20 and 40 minutes p.i.
For the whole group, the mean SUV on FET-PET was 2.3 ± 0.9 (range,
Discussion
We found a high correlation between the uptake of MET and FET in normal cortex and tumor tissue (brain gliomas and metastases). In gliomas both PET investigations give additional information in comparison to MRI concerning the location of the residual/progressive tumor. Both FET- and MET-PET showed a high sensitivity and specificity for tumor tissue of 91% and 100%, respectively, making it possible to differentiate brain gliomas and metastases from TRCs. These findings support the use of FET as
Conclusion
This is the first larger trial evaluating the use of FET-PET in comparison to MET-PET in determining tumor extension for treatment planning and monitoring in gliomas and brain metastases in the same group of patients investigated with both tracers within the same day. The study included patients with brain lesions (gliomas and metastases) after therapy: surgery, radiation therapy, and chemotherapy. The study showed that FET-PET and MET-PET provide comparable diagnostic information: (1) Uptake
References (36)
- et al.
Stereotactichistologic correlations of CT- and MRI-defined abnormalities in patients with glial neoplasms
Mayo Clin Proc
(1987) - et al.
Clinical features, mechanisms and management of pseudoprogression in malignant gliomas
Lancet Oncol
(2008) - et al.
L-(methyl-11C) methionine positron emissions tomography for target delineation in resected high grade gliomas before radiation therapy
Int J Radiat Oncol Biol Phys
(2005) - et al.
Re-irradiation of recurrent high grade gliomas using amino-acids-PET(SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy
Int J Radiat Oncol Biol Phys
(2005) - et al.
Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas
Nucl Med Biol
(2003) - et al.
Implications of IMT-SPECT for postoperative radiation treatment planning in patients with gliomas
Int J Radiat Oncol Biol Phys
(2002) - et al.
Imaged-based stereotaxic serial biopsies in untreated intracranial glial neoplasm
J Neurosurg
(1987) - et al.
Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas
Neurology
(1988) Imaging of gliomas
Semin Oncol
(1994)- et al.
MR imaging of cerebral metastatic disease
Adv MRI Contrast
(1996)
Predilection of brain metastases in gray and white matter junction and vascular border zones
Cancer
MR imaging of the brain tumors
Eur Radiol
Incidence of early pseudo-progression in a cohort of malignant gliomas patients treated with chemoirradiation with temozolomide
Cancer
Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference
Acta Radiol
Regional methionine and glucose uptake in high-grade gliomas: A comparative study on PET-guided stereotactic biopsy
J Nucl Med
Cranial neuronavigation with direct integration of (11)C methionine positron emission tomography (PET) data—Results of a pilot study in 32 surgical cases
Acta Neurochir (Wien)
Methionine positron tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery-in malignant glioma
Ann Nucl Med
Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas
J Nucl Med
Cited by (215)
ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma
2023, Radiotherapy and OncologyFacts and Fictions About [<sup>18</sup>F]FDG versus Other Tracers in Managing Patients with Brain Tumors: It Is Time to Rectify the Ongoing Misconceptions
2022, PET ClinicsCitation Excerpt :Another advantage of [18F]FET is its lower uptake in inflammatory cells compared with [11C]MET.58,59 Similar clinical performances are reported for [11C]MET and [18F]FET in the management of gliomas and metastases.66 In a meta-analysis assessing the diagnostic performance of [18F]FET and [18F]FDG PET in suspected brain tumors, Dunet and colleagues32 demonstrated a significantly higher sensitivity of [18F]FET PET (0.94; 95% CI, 0.79–0.98) compared with [18F]FDG (0.38; 95% CI, 0.27–0.50) for the diagnosis of brain tumor versus nontumoral lesions, with comparable specificity (0.88; 95% CI, 0.37–0.99, and 0.86; 95% CI, 0.31–0.99, respectively).
<sup>99m</sup>Tc(CO)<inf>3</inf>-labeled 1-(2-Pyridyl)piperazine derivatives as radioligands for 5-HT<inf>7</inf> receptors
2024, Annals of Nuclear Medicine
Conflict of interest: none.